Monday, February 4, 2013

Monday, February 4, 2013

Six-in-one vaccine is goal of GSK's Indian joint venture

GlaxoSmithKline created a joint venture with India's Biological E Ltd., to develop a six-in-one drug to combat several ailments, including polio, in developing nations.

Six-in-one vaccine is goal of GSK's Indian joint venture

POSTED: Tuesday, January 29, 2013, 6:22 AM

David Sell

Vaccines sometimes work wonderfully in a modern laboratory with great facilities and healthy patients (or parents of patients) who can follow all directions, but.....

Does it work in places with no modern health-care facilities?

Does it work in places with no electricity or sporadic power?

Does it work without refrigeration (see electricity above)?

Does it work in places without clean water?

Does it work if the dosing regime is complex, perhaps requiring numerous returns visits to clinics that are many miles away on foot?

Does it work when many of those things conspire to make patients less healthy?

All of those are the challenges for vaccine developers and the people who earnestly try to deliver good medicine in difficult environments.

And often those two groups don't see costs in the same way.

To that end - and to build its pharmaceutical business in the growing but increasingly complex and competitive Indian market - drugmaker GlaxoSmithKline said it struck a deal with India’s Biological E Ltd., to develop a six-in-one drug to combat several ailments, including polio, in developing nations.

GSK is based in London, but has several facilities in and around Philadelphia.

The idea of this vaccine is to combine GSK’s injectable polio vaccine and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough (whole cell pertussis), hepatitis B, and Haemophilus influenzae type B. This project is just starting, so any success will be years away, following testing.

As Bloomberg's Ketaki Gokhale noted in a story, GSK faces competition from Paris-based Sanofi in the market for injectable polio vaccine. Also the Serum Institute of India Ltd., is trying to increase its share of the market in developing countries.

According to a World Health Organization report published in October, 2012, India "stopped" polio by January 2011, leaving Afghanistan, Pakistan and Nigeria as the only countries were it was still endemic. A link to the WHO fact sheet is here.

“We are delighted to be working with Biological E., an established company in the global vaccine market," GSK president of vaccines, Christophe Weber, said in a statement. "This agreement is fully aligned to GSK’s vision of providing high quality vaccines to those in need and by leveraging Biological E’s strengths, this particular vaccine has the potential to be play a significant role in the fight against polio.”

Previous Story: Earnings previews from Bernstein analyst Tim Anderson

Next Story: Judge compares pill mill doctors to street drug dealers, and not favorably

Comments (4)

0 like this / 0 don't • Posted 9:32 AM, 01/29/2013

No thanks

— jkt

0 like this / 0 don't • Posted 7:05 PM, 01/30/2013

6 in 1, 10 in 1, 500 in 1. This is all pure unadulterated insanity vaccines are not safe-have never been proved to be safe. Children are sicker than ever. 1 in 54 boys with autism, 1 in 10 with asthma, 1 in 20 with diabetes. It's all about power and money and certainly not about the health and safety of our children.
Maurine Meleck, sc

— maurinemeleck

0 like this / 0 don't • Posted 8:37 PM, 01/30/2013

1. The current 5-in-1 Indian vaccine from which the 6-in-1 vaccine already appears to be killing children shortly after they are inoculated with it (http://www.naturalnews.com/038882_vaccine_deaths_children_India.html).
2. A recent study that shows the risk of hospitalization and death increases as more vaccine components are delivered at once (http://het.sagepub.com/content/31/10/1012, "Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990–2010" by Goldman GS and Miller NZ in Hum Exp Toxicol 2012 Oct; 31(10): 1012-1021, where the less toxic acellular pertussis components are used).
3. Based on points "1." and "2.", the resultant 6-in-1 vaccine should be even more toxic to the children inoculated with it than the current 5-in-1 vaccine is.

In light of the preceding three (3) realities, UNLESS the goal of the 6-in-1 vaccine is to kill and maim more children in India and other Asian countries than the current 5-in-1 vaccine is currently doing, this effort shouold be abandoned.

— drking333

0 like this / 0 don't • Posted 11:51 PM, 01/30/2013

"The current 5-in-1 Indian vaccine from which the 6-in-1 vaccine already appears to be killing children . . . "

(1) You might try to discern the difference between REAL data and the dreck that you glean from wacky web sites like Natural News, since the information from Natural News is directly contradicted by the current scientific literature.

(2) You also might try to understand, as the authors of that dreadful paper that you cited did not, that a DENOMINATOR is a rather critical component of a fraction. The VAERS site clearly indicates this, as you (or the authors) must have clicked past this notice:

"Please read the following statement on the limits of VAERS data. You MUST click on the box below to access the VAERS database. When reviewing data from VAERS, please keep in mind the following limitations: "A report to VAERS generally does not prove that the identified vaccine(s) caused the adverse event described. It only confirms that the reported event occurred sometime after vaccine was given. No proof that the event was caused by the vaccine is required in order for VAERS to accept the report. VAERS accepts all reports without judging whether the event was caused by the vaccine. . . . Note that the inclusion of events in VAERS data does not infer causality."

The work that you cite is therefore meaningless--as you and the authors of that pathetic paper should have understood.

— bepatienz